Want to join the conversation?
$BDX 3Q15 Q&A: Michael from JPMorgan asked about the opportunity in Infusion in China, and Thomas said I'll break the opportunity into time horizon approach across both consumables & capital. We've recently launched CareFusion IV needless connectors through our sales channel in China and also we are looking to launch related Infusion sets.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.
$VZ down more than 2% after a disappointing third quarter. A lot of uncertainty on the Yahoo deal too.